Disease-modifying therapy for multiple sclerosis

Tidsskr Nor Laegeforen. 2021 May 10;141(8). doi: 10.4045/tidsskr.21.0155. Print 2021 May 25.
[Article in English, Norwegian]
No abstract available

Plain language summary

High-efficacy therapy from the time of diagnosis substantially improves the prognosis for multiple sclerosis. The national guidelines on MS nevertheless recommend less effective therapy for many patients, and must be updated in pace with medical advances. We consider in the following how multiple sclerosis should be treated.

MeSH terms

  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Multiple Sclerosis* / drug therapy

Substances

  • Immunosuppressive Agents